{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04044534",
            "orgStudyIdInfo": {
                "id": "GY0005"
            },
            "organization": {
                "fullName": "VA Connecticut Healthcare System",
                "class": "FED"
            },
            "briefTitle": "Intranasal Insulin for Posttraumatic Stress Disorder",
            "officialTitle": "Intranasal Insulin for Treating Posttraumatic Stress Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "intranasal-insulin-for-posttraumatic-stress-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-08-01",
            "studyFirstSubmitQcDate": "2019-08-01",
            "studyFirstPostDateStruct": {
                "date": "2019-08-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Gihyun Yoon, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "VA Connecticut Healthcare System"
            },
            "leadSponsor": {
                "name": "VA Connecticut Healthcare System",
                "class": "FED"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate if intranasal insulin is effective in reducing PTSD symptoms.",
            "detailedDescription": "The current proposal aims to study the pharmacotherapeutic effects of intranasal insulin on PTSD symptoms and inhibition of amygdala hyperactivation in subjects with PTSD."
        },
        "conditionsModule": {
            "conditions": [
                "PTSD"
            ],
            "keywords": [
                "Intranasal insulin",
                "PTSD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intranasal insulin",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive 40 IU of intranasal insulin twice a day (80 IU per day).",
                    "interventionNames": [
                        "Drug: Intranasal insulin"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects in this arm will receive placebo.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Intranasal insulin",
                    "description": "Subjects in this arm will receive intranasal insulin (80 IU per day).",
                    "armGroupLabels": [
                        "Intranasal insulin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Subjects in this arm will receive placebo.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Post-traumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)",
                    "description": "The five-point CAPS-5 consists of 20 PTSD symptoms rated on a 0-4 scale (total range: 0-80) as follows: (1) 5 Intrusion symptoms (0-20), (2) 2 Avoidance symptoms (0-8), (3) 7 Cognitions and mood symptoms (0-28), and (4) 6 Arousal and reactivity symptoms (0-24). Higher scores represent a worse outcome (i.e., more PTSD symptoms).",
                    "timeFrame": "1 week"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, 21-65 years old\n* Current PTSD\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Unstable medical condition, clinically determined by a physician\n* Diabetes requiring insulin or oral hypoglycemic agents\n* Moderate-severe traumatic brain injury\n* Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months\n* Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months\n* Changes in doses of psychotropic medications in the past 4 weeks\n* Initiation of individual therapy or counseling in the past 4 weeks\n* Imminent suicidal or homicidal risk\n* Contraindication to Insulin\n* History of claustrophobia\n* Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety screening questionnaire",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gihyun Yoon, MD",
                    "role": "CONTACT",
                    "phone": "(203) 932-5711",
                    "phoneExt": "7421",
                    "email": "gihyun.yoon@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gihyun Yoon, MD",
                    "affiliation": "VA Connecticut Healthcare System",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "VA Connecticut Healthcare System",
                    "status": "RECRUITING",
                    "city": "West Haven",
                    "state": "Connecticut",
                    "zip": "06516",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gihyun Yoon, MD",
                            "role": "CONTACT",
                            "phone": "203-932-5711",
                            "phoneExt": "7421",
                            "email": "gihyun.yoon@yale.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.27065,
                        "lon": -72.94705
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013313",
                    "term": "Stress Disorders, Post-Traumatic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000040921",
                    "term": "Stress Disorders, Traumatic"
                },
                {
                    "id": "D000068099",
                    "term": "Trauma and Stressor Related Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M24916",
                    "name": "Stress Disorders, Traumatic",
                    "relevance": "LOW"
                },
                {
                    "id": "M16103",
                    "name": "Stress Disorders, Post-Traumatic",
                    "asFound": "Posttraumatic Stress Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17685",
                    "name": "Wounds and Injuries",
                    "relevance": "LOW"
                },
                {
                    "id": "M222",
                    "name": "Trauma and Stressor Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007328",
                    "term": "Insulin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "asFound": "Day 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}